Tumour necrosis factor-α (-308) gene polymorphism in obstructive sleep apnoea-hypopnoea syndrome Source: Eur Respir J 2005; 26: 673-678 Year: 2005
CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea Source: Eur Respir J 2008; 32: 1009-1015 Year: 2008
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea}, Source: Eur Respir J 2012; 40: 1046-1048 Year: 2012
Plasma levels of TNF in obstructive sleep apnea syndrome (OSA) before and after surgical intervention Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012
Plasma vascular endothelial growth factor levels in patients with obstructive sleep apnea hypopnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 564s Year: 2004
Serum leptin and tumor necrosis factor – alpha levels and maximal exercise performance in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Respiratory muscles in disease Year: 2008
Study of inflammatory markers (C-reactive protein & tumor necrosis factor-α) in moderate to severe obstructive sleep apnea hypopnea syndrome (OSAHS) and their response to treatment with nasal continuous positive airway pressure (nCPAP) Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009
Sleep apnoea and metabolic dysfunction}, Source: Eur Respir Rev 2013; 22: 353-364 Year: 2013
C-reactive protein levels can predict obstructive sleep apnea / hypopnea syndrome? Source: Eur Respir J 2004; 24: Suppl. 48, 118s Year: 2004
The growth hormone receptor +561G allele is associated with obesity and the obstructive sleep apnoea/hypopnoea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Frequency of distribution of IL-1, IL-6 and TNFa gene polymorphism in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2006 - Metabolic control in obstructive sleep apnoea Year: 2006
Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008
Sleep apnoea and the heart}, Source: Eur Respir Rev 2013; 22: 333-352 Year: 2013
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005
Leptin, interleukin-6 and tumor necrosis factor-alpha in patients with obstructive sleep apnea syndrome Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
The role of complement factor H and clusterin in obstructive sleep apnoea Source: Virtual Congress 2020 – Pathophysiology and treatment of obstructive sleep apnoea Year: 2020
Ambulatory monitoring in the diagnosis and management of obstructive sleep apnoea syndrome}, Source: Eur Respir Rev 2013; 22: 312-324 Year: 2013
The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Does low plasma adiponectin level affect cardiovasculer risk in obstructive sleep apnea syndrome? Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Serum adiponectin, hs- C-reactive protein and tumor necrosis factor-alpha levels In patients with obstructive sleep apnea syndrome: Effect of CPAP Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010